Naltrexone 50 Mg
DrugNaltrexone 25 or 50 mg per titration schedule
NCT Number: NCT00920829
The overarching aim of this trial is to evaluate naltrexone's efficacy in light of genetic variation and brain response to alcohol cues utilizing a neuroimaging paradigm. This trial has four specific aims. First, this trial will evaluate whether the presence of the OPRM1 Asp40 allele substitution is associated with improved treatment response to naltrexone in treatment-seeking alcoholics. Second, it will evaluate whether there is a difference in the naltrexone dampening of the alcohol cue-induced brain activation dependent on OPRM1 genotype. Third, it will explore whether alcohol cue-induced brain activation dampening by naltrexone might be a mediating factor in the treatment effects of naltrexone, the OPRM1 gene, or their interaction that might be observed in the first aim. Finally, this trial will evaluate the effect of medication compliance, or adverse effects, on the observed medication by genotype treatment response. A secondary aim will measure medication compliance and side effects based on OPRM1 genotype.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 4
Medical University of South Carolin, Charleston, South Carolina, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion criteria
of fMRI Procedure
Naltrexone 25 or 50 mg per titration schedule
placebo
Time frame: Time Line Follow-Back drinking collected at each of 9 visits (weeks 1, 2, 3, 4, 6, 8, 10, 12 and 16)
Medical University of South Carolina
Other
Genetic and Brain Mechanisms of Naltrexone?s Treatment Efficacy for Alcoholism
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04581499
Alcohol Dependence, Alcohol Use Disorder
Boston, Massachusetts, United States
View Trial DetailsNCT02564991
Alcohol Dependence, Alcohol-Related Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT03696888
Alcohol Abuse, Alcohol Dependence
Stockholm, Sweden
View Trial DetailsNCT00842036
Alcohol Dependence, Alcohol-Related Disorders
Philadelphia, Pennsylvania, United States
View Trial Details